Patent application number | Description | Published |
20100008980 | Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer - A combination therapy comprising an immunotherapy based on a tumour antigen or an immunological derivative thereof, and at least one other treatment for cancer such as chemotherapy, radiotherapy and/or surgery. | 01-14-2010 |
20100021424 | Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy - The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles and new diagnostic kits and methods. The invention further relates to treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from Mage expressing tumours. | 01-28-2010 |
20100029912 | Fusion Protein - Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells. | 02-04-2010 |
20100247580 | Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy - The present invention relates to gene expression profiles; methods for classifying patients; microarrays; and treatment of population of patients selected through use of methods and microarrays as described herein. | 09-30-2010 |
20110070268 | Method - Methods for characterisation of patients as responders or non-responders to therapy based on differential expression of one or more genes are provided. Gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and new diagnostic kits and methods of treatment are also provided. The kits and methods relate to the treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from MAGE expressing tumours. | 03-24-2011 |